Patients with the *36/*36 genotype may have an increased risk of developing respiratory depression when treated with sufentanil as compared to patients with the *1/*1 or *1/*36 genotypes. Other genetic and clinical factors may also affect a patient's risk of respiratory depression when treated with sufentanil.